EUVIMEDEUVIMED entdecken
Open Access

No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis

Dhruv Ahuja, Guangyong Zou, Virginia Solitano, Gaurav Syal, Han Hee Lee, Christopher Ma, Vipul Jairath, Siddharth Singh

Clinical Gastroenterology and Hepatology · 2025

DOI: 10.1016/j.cgh.2024.08.040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025. Verfasst von Dhruv Ahuja und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Indira Gandhi Hospital, New Delhi, India. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Although participants with inflammatory bowel diseases in clinical trials of biologics and small molecule drugs (henceforth, advanced therapies) frequently receive several medications concomitantly, it is unclear how they modify treatment effect. METHODS: Through an individual patient data pooled analysis of 10 clinical trials of advanced therapies for moderate-to-severe ulcerative colitis, we assessed whether concomitant exposure to corticosteroids, immunomodulators, mesalamine, proton pump inhibitors, histamine receptor antagonists, opiates, antidepressants, and antibiotics modified the effect of the intervention on treatment efficacy and safety outcomes, using modified Poisson regression model. RESULTS: Of 6044 patients (4280 receiving intervention, 1764 receiving placebo), several received concomitant corticosteroids (47%), immunomodulators (28%), mesalamine (68%), proton pump inhibitors (14%), histamine receptor antagonists (2%), opiates (7%), antidepressants (6%), and/or antibiotics (5%). After adjusting for confounders and examining treatment efficacy of intervention versus placebo, we observed no impact of concomitant exposure to corticosteroids (ratio of relative risk of drug vs placebo with vs without concomitant exposure: ratio of risk ratio [RRR], 0.81 [95% confidence interval, 0.63-1.06]), mesalamine (RRR, 1.04 [0.78-1.39]), proton pump inhibitors (RRR, 0.87 [0.61-1.22]), histamine receptor antagonists (RRR, 1.72 [0.97-14.29]), opiates (RRR, 0.90 [0.54-1.49]), antidepressants (RRR, 1.02 [0.57-1.83]), and antibiotics (RRR, 0.72 [0.44-1.16]) on likelihood of clinical remission. Concomitant exposure to immunomodulators was associated with lower likelihood of achieving clinical remission (RRR, 0.73 [0.55-0.97]), particularly with non-tumor necrosis factor antagonists. CONCLUSIONS: In clinical trials of advanced therapies for ulcerative colitis, baseline concomitant exposure to multiple commonly used class of medications does not impact treatment efficacy or safety. These findings directly inform design of regulatory clinical trials with respect to managing concomitant medications at baseline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBiological ProductsHumansMaleAdultFemaleMiddle AgedTreatment OutcomeDrug Therapy, CombinationYoung AdultAgedPlacebos

Stichwörter der Autor:innen

Concomitant MedicationsInflammatory Bowel DiseasesTrial DesignUstekinumabVivli

Substanzen

Biological ProductsPlacebos

Autor:innen und Institutionen

  • Department of Medicine, Indira Gandhi Hospital, New Delhi, India.
  • Alimentiv Inc, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
  • Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, Canada; Division of Gastroenterology and Gastrointestinal Endoscopy, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raf…
  • Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California.
  • Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California; Division of Gastroenterology, Department of Internal Medicine, Yeouido St. Mary's Hospital College of Medic…
  • Alimentiv Inc, London, Ontario, Canada; Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Department of Community Health Sciences, University of Ca…

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Ahuja, D., Zou, G., Solitano, V., Syal, G., Lee, H. H., Ma, C., Jairath, V., & Singh, S. (2025). No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.08.040

Vancouver

Ahuja D, Zou G, Solitano V, Syal G, Lee HH, Ma C, et al. No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2025. doi:10.1016/j.cgh.2024.08.040

BibTeX
@article{Ahuja2025,
  author = {Ahuja, Dhruv and Zou, Guangyong and Solitano, Virginia and Syal, Gaurav and Lee, Han Hee and Ma, Christopher and Jairath, Vipul and Singh, Siddharth},
  title = {No Impact of Concomitant Medications on Efficacy and Safety of Biologics and Small Molecules for Ulcerative Colitis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2025},
  doi = {10.1016/j.cgh.2024.08.040}
}
Kostenlos starten →